Abstract
Few treatment options exist for patients with advanced or recurrent endometrial cancer (EC) that has progressed after treatment with platinum-based therapy. Dostarlimab and pembrolizumab are approved for patients with advanced cancers that have not responded to prior therapy and are mismatch repair deficient (dMMR). This analysis aimed to add to the evidence on the cost-effectiveness of immunotherapy for advanced or recurrent dMMR EC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
